<DOC>
	<DOCNO>NCT00079105</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vinblastine , cyclophosphamide , procarbazine , prednisolone , etoposide , mitoxantrone , bleomycin , work different way stop cancer cell divide stop grow die . Combining one chemotherapy drug may kill cancer cell . PURPOSE : This phase II trial study well combination chemotherapy work treat old patient previously untreated Hodgkin 's lymphoma .</brief_summary>
	<brief_title>A Phase II Study VEPEMB In Patients With Hodgkin 's Lymphoma Aged ≥ 60 Years</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy toxicity vinblastine , cyclophosphamide , procarbazine , prednisolone , etoposide , mitoxantrone , bleomycin old patient Hodgkin 's lymphoma . - Determine whether application Hasenclever prognostic index valid patient diagnosis . OUTLINE : This open-label , multicenter study . - Chemotherapy : Patients receive vinblastine IV cyclophosphamide IV day 1 ; oral procarbazine oral prednisolone day 1-5 ; oral etoposide day 15-19 ; mitoxantrone IV bleomycin IV day 15 . Treatment repeat every 28 day , absence disease progression unacceptable toxicity , total 3 course patient early ( stage IA IIA ) disease 6 course patient advance ( stage IB IIB-IV ) disease . - Radiotherapy : Patients early stage disease receive involved-field radiotherapy . Patients advanced stage disease receive radiotherapy limit site initial bulky disease residual disease . Radiotherapy begin 4 week completion chemotherapy . Patients follow monthly 3 month , every 3 month 6 month , annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 150 patient accrue study within 36 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm classical Hodgkin Lymphoma ( HL ) . No previous treatment HL . Age ≥ 60 . `` Non fragile '' patient ( see Appendix 1 ) i.e . patient 's mental physical status must sufficient withstand treatment describe . No concomitant neoplasia require treatment know HIV infection . Written informed consent . Exclusion criterion : Nodular lymphocyte predominance Hodgkin Lymphoma ( NLPHL ) Age &lt; 60 . Patient previously treat HL . Known HIV infection concomitant neoplasia . `` Fragile patient '' ( see Appendix 1 ) significant abnormality another system ( pulmonary , cardiac , renal , hepatic ) contraindication full dose chemotherapy . Unable give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
</DOC>